News

Filter

Current filters:

EliquisXareltoResearch

“Breakthrough Therapy” status for Portola’s andexanet alfa

25-11-2013

USA-based Portola Pharmaceuticals has been granted “Breakthrough Therapy” designation by the US Food…

andexanet alfaBayerBristol-Myers SquibbCardio-vascularEliquisNorth AmericaPharmaceuticalPortola PharmaceuticalsRegulationResearchXarelto

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

19-11-2013

Presented for the first time at the American Heart Association’s (AHA) Scientific Sessions, results…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPharmaceuticalPradaxaResearchXarelto

Bayer’s Xarelto significantly reduced mortality in major ACS study; Bristol-Myers’ Eliquis fails endpoint in VTE trial

14-11-2011

The US unit of Germany’s Bayer (BAY: DE) yesterday announced that the combination of oral Xarelto…

BayerBristol-Myers SquibbCardio-vascularEliquisJohnson & JohnsonPfizerPharmaceuticalResearchXarelto

Pfizer and B-MS’ blood thinner Eliquis better than expected in Ph III trial

24-06-2011

US drug majors Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) had a significant boost when they…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPradaxaResearchXarelto

Back to top